Skip to Main Content

Paper Details

The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial.
Diabetes Metab
4
2022
Author NameAffiliation
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto
Kenneth W MahaffeyStanford Centre for Clinical Research, Stanford University School of Medicine
  • 1 - 2

Datasets

Release 1.2